ARTemis: A randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer-Primary endpoint, pathological complete response (pCR).
Authors: Earl, H.M., Hiller, L., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Abraham, J., Thomas, J., Provenzano, E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Houston, S., Rea, D., Bartlett, J.M.S., Caldas, C., Cameron, D.A., Dunn, J., Hayward, R.L.
Journal: JOURNAL OF CLINICAL ONCOLOGY
Publication Date: 20/05/2014
Volume: 32
Issue: 15
eISSN: 1527-7755
ISSN: 0732-183X
DOI: 10.1200/jco.2014.32.15_suppl.1014
Source: Web of Science
ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR).
Authors: Hickish, Earl, H., Hiller, L., Dunn, J., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Abraham, J., Thomas, J., Provenzano, E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Houston, S., Rea, D., Bartlett, J., Caldas, C., Cameron, D., Hayward, L.
Conference: NCRI Cancer Conference in the Clinical Trials Showcase
Dates: 02/11/2014
Publication Date: 02/11/2014
Source: Manual
Preferred by: Tamas Hickish